double-blinded treatment peri od and they received one dose of open-label once-weekly exenatide at a timepoint after week 26.The 52-week evaluable population consisted of the open-labelintent-to-treat patients who completed the study visits to at leastDIABETIC Medicine DURATION-2: switching from sitagliptin or pioglitazone to exenatide once-weekly •C. Wysham et al. ª2011 Amylin Pharmaceuticals, Inc. 706 Diabetic Medicine ª2011 Diabetes UK